TrialReader


Analysis of Stannous Fluoride in GCF and Subgingival Plaque

NCT03296657 — Not applicable, Completed, 20 participants, Procter and Gamble

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

A Pilot Study to Evaluate Stannous Fluoride in GCF and Subgingival Plaque

RegistryNCT03296657
StatusCompleted
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, basic science
Enrollment20 (Actual)
SponsorProcter and Gamble (Industry)
ConditionsSubgingival Plaque, GCF
Interventionsstannous fluoride (Drug)
Datesstart 2017-08-23, primary completion 2017-09-22, completion 2017-09-22, first posted 2017-09-28, last updated 2017-11-06
Locations1 site in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Subgingival Plaque All trials for GCF All trials of stannous fluoride

-Summary

The amount of stannous fluoride in GCF and subgingival plaque samples will be analyzed.

Expand all sections  ·  Collapse all

+Detailed description

This is pilot study involving approximately 20 subjects with at least 20 dental pockets between 2- 4mm with bleeding for sampling. Subjects will have up to 10 sites identified as "sampling sites" that will have supragingival plaque, subgingival plaque, and gingival crevicular fluid (GCF) collected at Baseline, 30 minutes, 24 hours, and Week 2.

+Arms and interventions

ArmTypeInterventionsDescription
stannous fluoride toothpasteExperimentalDrug: stannous fluoride0.454% stannous fluoride will be used twice a day, brushing for at least 1 minute for 2 weeks
  • stannous fluoride (Drug): subjects will brush with paste twice daily for 2 weeks

+Outcome measures

Primary outcomes

  • Amount of tin in GCF sample [mean difference from 30 minutes to baseline]: per GCF sample amount of stannous level in ng/uL will be measured

Secondary outcomes

  • Amount of tin in GCF and Subgingival Plaque [change from visit (change from 24 hours to baseline, change Week 2 to baseline)]: stannous level in subgingival plaque will be measured as concentration in ng, per GCF sample amount of stannous level in ng/uL

+Eligibility

Sex: All, ages: 18 Years to any, accepts healthy volunteers

Inclusion Criteria:

* Provide written informed consent to participate in the study;
* Be 18 years of age or older;
* Agree not to participate in any other oral/dental product studies during the course of this study;
* Agree to delay any elective dentistry (including dental prophylaxis) until the study has been completed;
* Agree to use the acclimation products and to refrain from using any other oral care products (including floss and mouth rinse) between the Acclimation and Baseline Visit;
* Agree to use the treatment products and refrain from any form of non-specified oral hygiene during the treatment periods (after the Baseline Visit), including but not limited to the use of products such as floss, mouth rinse, or whitening products;
* Agree to return for all scheduled visits and follow study procedures;
* Must have at least 16 natural teeth;
* Be in good general health, as determined by the Investigator/designee based on a review of the health history/update for participation in the study;
* Agree to refrain from all oral hygiene after 11 p.m. the night prior to each visit;
* Agree to refrain from eating, chewing gum, drinking and using tobacco for 4 hours prior to each visit;
* Have minimum 20 sampling sites with bleeding and pocket depth ≥2mm but not deeper than 4mm.

Exclusion Criteria:

* Having a dental prophylaxis within 2 weeks of Acclimation visit;
* Having rampant caries, open or untreated caries, or advanced periodontitis requiring prompt treatment;
* A medical condition requiring an antibiotic prophylaxis prior to dental visits;
* A history of hypersensitivity to oral care products containing stannous fluoride; or
* Have any condition or disease, as determined by the Investigator/Designee based on a review of the medical history, which could be expected to interfere with examination procedures or with the subject's safe completion of the study.

+Locations (1)

FacilityCityCountryStatus
Salus ResearchFort Wayne, IndianaUnited States

+Investigators

My Notes